Athira Pharma Inc (NASDAQ: ATHA) is -48.47% lower on its value in year-to-date trading and has touched a low of $0.22 and a high of $3.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATHA stock was last observed hovering at around $0.29 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.30, the stock is 10.18% and 10.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.78 million and changing 6.03% at the moment leaves the stock -51.62% off its SMA200. ATHA registered -88.05% loss for a year compared to 6-month loss of -53.71%. The firm has a 50-day simple moving average (SMA 50) of $0.27524 and a 200-day simple moving average (SMA200) of $0.63787.
The stock witnessed a 4.97% gain in the last 1 month and extending the period to 3 months gives it a -19.17%, and is 5.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.49% over the week and 5.97% over the month.
Athira Pharma Inc (ATHA) has around 26 employees, a market worth around $11.80M and $0.00M in sales. Distance from 52-week low is 37.69% and -91.76% from its 52-week high. The company has generated returns on investments over the last 12 months (-209.74%).
The EPS is expected to grow by 75.66% this year.
Athira Pharma Inc (ATHA) Top Institutional Holders
65.0 institutions hold shares in Athira Pharma Inc (ATHA), with institutional investors hold 49.72% of the company’s shares. The shares outstanding are 39.04M, and float is at 33.69M with Short Float at 2.23%. Institutions hold 45.61% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 5.4 million shares valued at $14.32 million. The investor’s holdings represent 14.0776% of the ATHA Shares outstanding. As of 2024-06-30, the second largest holder is BAKER BROS. ADVISORS LP with 3.15 million shares valued at $$8.36 million to account for 8.2174 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.63 million shares representing 4.2586% and valued at over $4.33 million, while SIMPLIFY ASSET MANAGEMENT INC. holds 3.8895 of the shares totaling 1.49 million with a market value of $3.96 million.
Athira Pharma Inc (ATHA) Insider Activity
The most recent transaction is an insider sale by San Martin Javier,the company’sCHIEF MEDICAL OFFICER. SEC filings show that San Martin Javier sold 10,826 shares of the company’s common stock on Jan 02 ’25 at a price of $0.56 per share for a total of $6083.0. Following the sale, the insider now owns 35841.0 shares.
Athira Pharma Inc disclosed in a document filed with the SEC on Jan 02 ’25 that Litton Mark James (President and CEO) sold a total of 25,107 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $0.56 per share for $14108.0. Following the transaction, the insider now directly holds 0.24 million shares of the ATHA stock.
Still, SEC filings show that on Jan 02 ’25, CHURCH KEVIN (CHIEF SCIENTIFIC OFFICER) disposed off 8,510 shares at an average price of $0.56 for $4782.0. The insider now directly holds 130,761 shares of Athira Pharma Inc (ATHA).
